Regeneron Pharmaceuticals, Inc. (0R2M.L)
USD 732.14
(-1.06%)
USD 732.14
(-1.06%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 4.04 Billion USD | -14.6% |
| 2022 | 4.73 Billion USD | -47.03% |
| 2021 | 8.94 Billion USD | 150.15% |
| 2020 | 3.57 Billion USD | 61.85% |
| 2019 | 2.2 Billion USD | -12.81% |
| 2018 | 2.53 Billion USD | 21.87% |
| 2017 | 2.07 Billion USD | 56.27% |
| 2016 | 1.33 Billion USD | 6.3% |
| 2015 | 1.25 Billion USD | 49.32% |
| 2014 | 838.43 Million USD | 10.32% |
| 2013 | 760.02 Million USD | 66.05% |
| 2012 | 457.71 Million USD | 323.1% |
| 2011 | -205.15 Million USD | -110.48% |
| 2010 | -97.47 Million USD | -31.54% |
| 2009 | -74.1 Million USD | 17.51% |
| 2008 | -89.83 Million USD | 21.51% |
| 2007 | -114.45 Million USD | -6.32% |
| 2006 | -107.65 Million USD | -186.52% |
| 2005 | 124.42 Million USD | 2103.7% |
| 2004 | 5.64 Million USD | 105.65% |
| 2003 | -99.98 Million USD | 18.01% |
| 2002 | -121.95 Million USD | -42.33% |
| 2001 | -85.68 Million USD | -238.99% |
| 2000 | -25.27 Million USD | -6.2% |
| 1999 | -23.8 Million USD | -88.89% |
| 1998 | -12.6 Million USD | -68.0% |
| 1997 | -7.5 Million USD | 56.65% |
| 1996 | -17.3 Million USD | -127.63% |
| 1995 | -7.6 Million USD | 73.97% |
| 1994 | -29.2 Million USD | 24.74% |
| 1993 | -38.8 Million USD | -112.02% |
| 1992 | -18.3 Million USD | -90.63% |
| 1991 | -9.6 Million USD | -190.91% |
| 1990 | -3.3 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 1.09 Billion USD | 44.17% |
| 2024 Q1 | 758.5 Million USD | -22.04% |
| 2024 Q3 | 1.17 Billion USD | 7.86% |
| 2023 Q3 | 1.11 Billion USD | 9.3% |
| 2023 FY | 4.04 Billion USD | -14.6% |
| 2023 Q2 | 1.01 Billion USD | 7.37% |
| 2023 Q1 | 946.7 Million USD | -17.45% |
| 2023 Q4 | 972.9 Million USD | -12.43% |
| 2022 Q4 | 1.14 Billion USD | -6.28% |
| 2022 Q2 | 1.1 Billion USD | -11.81% |
| 2022 Q1 | 1.25 Billion USD | -52.32% |
| 2022 Q3 | 1.22 Billion USD | 10.25% |
| 2022 FY | 4.73 Billion USD | -47.03% |
| 2021 Q1 | 1.11 Billion USD | -4.65% |
| 2021 Q3 | 1.84 Billion USD | -44.81% |
| 2021 Q4 | 2.63 Billion USD | 42.9% |
| 2021 FY | 8.94 Billion USD | 150.15% |
| 2021 Q2 | 3.34 Billion USD | 200.82% |
| 2020 Q3 | 1.05 Billion USD | 60.44% |
| 2020 FY | 3.57 Billion USD | 61.85% |
| 2020 Q2 | 656.4 Million USD | -6.24% |
| 2020 Q1 | 700.1 Million USD | 3.61% |
| 2020 Q4 | 1.16 Billion USD | 10.82% |
| 2019 FY | 2.2 Billion USD | -12.81% |
| 2019 Q4 | 675.7 Million USD | -8.5% |
| 2019 Q3 | 738.5 Million USD | 134.0% |
| 2019 Q2 | 315.6 Million USD | -34.25% |
| 2019 Q1 | 480 Million USD | -33.16% |
| 2018 Q4 | 718.1 Million USD | 14.54% |
| 2018 FY | 2.53 Billion USD | 21.87% |
| 2018 Q3 | 626.92 Million USD | 0.76% |
| 2018 Q2 | 622.18 Million USD | 9.69% |
| 2018 Q1 | 567.23 Million USD | 5.27% |
| 2017 Q1 | 430.54 Million USD | 24.07% |
| 2017 FY | 2.07 Billion USD | 56.27% |
| 2017 Q3 | 559.92 Million USD | 1.75% |
| 2017 Q4 | 538.81 Million USD | -3.77% |
| 2017 Q2 | 550.31 Million USD | 27.82% |
| 2016 Q4 | 347 Million USD | -4.35% |
| 2016 Q1 | 329.3 Million USD | 42.51% |
| 2016 Q2 | 291.62 Million USD | -11.44% |
| 2016 FY | 1.33 Billion USD | 6.3% |
| 2016 Q3 | 362.8 Million USD | 24.41% |
| 2015 Q3 | 392.42 Million USD | 13.79% |
| 2015 FY | 1.25 Billion USD | 49.32% |
| 2015 Q1 | 283.55 Million USD | 14.63% |
| 2015 Q2 | 344.85 Million USD | 21.62% |
| 2015 Q4 | 231.08 Million USD | -41.11% |
| 2014 Q4 | 247.36 Million USD | 35.38% |
| 2014 FY | 838.43 Million USD | 10.32% |
| 2014 Q1 | 185.93 Million USD | -12.32% |
| 2014 Q2 | 222.4 Million USD | 19.61% |
| 2014 Q3 | 182.71 Million USD | -17.84% |
| 2013 Q4 | 212.07 Million USD | -10.44% |
| 2013 FY | 760.02 Million USD | 66.05% |
| 2013 Q3 | 236.8 Million USD | 49.78% |
| 2013 Q2 | 158.1 Million USD | 3.3% |
| 2013 Q1 | 153.05 Million USD | 5.07% |
| 2012 FY | 457.71 Million USD | 323.1% |
| 2012 Q4 | 145.67 Million USD | -28.02% |
| 2012 Q1 | 22.2 Million USD | 148.9% |
| 2012 Q2 | 87.47 Million USD | 294.03% |
| 2012 Q3 | 202.36 Million USD | 131.33% |
| 2011 Q1 | -40.98 Million USD | -220.74% |
| 2011 Q4 | -45.4 Million USD | 22.33% |
| 2011 Q2 | -60.31 Million USD | -47.19% |
| 2011 FY | -205.15 Million USD | -110.48% |
| 2011 Q3 | -58.45 Million USD | 3.09% |
| 2010 Q2 | -23.72 Million USD | 17.22% |
| 2010 FY | -97.47 Million USD | -31.54% |
| 2010 Q3 | -32.09 Million USD | -35.28% |
| 2010 Q4 | -12.77 Million USD | 60.19% |
| 2010 Q1 | -28.65 Million USD | 27.28% |
| 2009 Q1 | -19.23 Million USD | 44.42% |
| 2009 Q2 | -16.26 Million USD | 15.42% |
| 2009 Q3 | -1.29 Million USD | 92.06% |
| 2009 Q4 | -39.4 Million USD | -2952.52% |
| 2009 FY | -74.1 Million USD | 17.51% |
| 2008 FY | -89.83 Million USD | 21.51% |
| 2008 Q4 | -34.59 Million USD | -73.59% |
| 2008 Q3 | -19.93 Million USD | -2.8% |
| 2008 Q2 | -19.38 Million USD | -21.86% |
| 2008 Q1 | -15.91 Million USD | -37.95% |
| 2007 Q3 | -38.66 Million USD | -26.35% |
| 2007 Q4 | -11.53 Million USD | 70.17% |
| 2007 FY | -114.45 Million USD | -6.32% |
| 2007 Q2 | -30.6 Million USD | 9.05% |
| 2007 Q1 | -33.64 Million USD | -0.49% |
| 2006 Q4 | -33.48 Million USD | -18.51% |
| 2006 FY | -107.65 Million USD | -186.52% |
| 2006 Q3 | -28.25 Million USD | -16.53% |
| 2006 Q2 | -24.24 Million USD | -11.94% |
| 2006 Q1 | -21.66 Million USD | -109.88% |
| 2005 Q3 | -34.38 Million USD | -6.9% |
| 2005 FY | 124.42 Million USD | 2103.7% |
| 2005 Q2 | -32.16 Million USD | -13.5% |
| 2005 Q1 | -28.34 Million USD | -813.14% |
| 2005 Q4 | 219.31 Million USD | 737.78% |
| 2004 Q1 | 23.79 Million USD | 238.83% |
| 2004 FY | 5.64 Million USD | 105.65% |
| 2004 Q4 | 3.97 Million USD | 141.92% |
| 2004 Q3 | -9.47 Million USD | 25.03% |
| 2004 Q2 | -12.64 Million USD | -153.14% |
| 2003 Q2 | -26.93 Million USD | 5.1% |
| 2003 Q4 | -17.13 Million USD | 33.32% |
| 2003 FY | -99.98 Million USD | 18.01% |
| 2003 Q3 | -25.7 Million USD | 4.56% |
| 2003 Q1 | -28.37 Million USD | 18.06% |
| 2002 Q2 | -29.95 Million USD | -18.88% |
| 2002 Q1 | -25.19 Million USD | 14.87% |
| 2002 Q3 | -32.17 Million USD | -7.43% |
| 2002 Q4 | -34.63 Million USD | -7.64% |
| 2002 FY | -121.95 Million USD | -42.33% |
| 2001 Q3 | -23.29 Million USD | -28.8% |
| 2001 FY | -85.68 Million USD | -238.99% |
| 2001 Q1 | -11.93 Million USD | -25.54% |
| 2001 Q2 | -18.08 Million USD | -51.48% |
| 2001 Q4 | -29.59 Million USD | -27.04% |
| 2000 Q3 | -4.58 Million USD | -15.27% |
| 2000 Q2 | -3.97 Million USD | 53.13% |
| 2000 FY | -25.27 Million USD | -6.2% |
| 2000 Q1 | -8.48 Million USD | -1111.43% |
| 2000 Q4 | -9.51 Million USD | -107.55% |
| 1999 Q1 | -9.3 Million USD | -50.0% |
| 1999 FY | -23.8 Million USD | -88.89% |
| 1999 Q4 | -700 Thousand USD | 86.27% |
| 1999 Q3 | -5.1 Million USD | 39.29% |
| 1999 Q2 | -8.4 Million USD | 9.68% |
| 1998 FY | -12.6 Million USD | -68.0% |
| 1998 Q3 | -2.4 Million USD | -442.86% |
| 1998 Q4 | -6.2 Million USD | -158.33% |
| 1998 Q1 | -4.9 Million USD | -508.33% |
| 1998 Q2 | 700 Thousand USD | 114.29% |
| 1997 Q3 | -1.1 Million USD | 70.27% |
| 1997 Q1 | -4.1 Million USD | 8.89% |
| 1997 FY | -7.5 Million USD | 56.65% |
| 1997 Q4 | 1.2 Million USD | 209.09% |
| 1997 Q2 | -3.7 Million USD | 9.76% |
| 1996 Q2 | -3.7 Million USD | 21.28% |
| 1996 Q4 | -4.5 Million USD | -2.27% |
| 1996 Q1 | -4.7 Million USD | -74.07% |
| 1996 FY | -17.3 Million USD | -127.63% |
| 1996 Q3 | -4.4 Million USD | -18.92% |
| 1995 FY | -7.6 Million USD | 73.97% |
| 1995 Q4 | -2.7 Million USD | -12.5% |
| 1995 Q3 | -2.4 Million USD | -84.62% |
| 1995 Q2 | -1.3 Million USD | 38.1% |
| 1995 Q1 | -2.1 Million USD | 58.82% |
| 1994 Q2 | -10 Million USD | 3.85% |
| 1994 Q4 | -5.1 Million USD | -37.84% |
| 1994 FY | -29.2 Million USD | 24.74% |
| 1994 Q3 | -3.7 Million USD | 63.0% |
| 1994 Q1 | -10.4 Million USD | 7.14% |
| 1993 Q2 | -9.8 Million USD | -6.52% |
| 1993 Q4 | -11.2 Million USD | -20.43% |
| 1993 Q3 | -9.3 Million USD | 5.1% |
| 1993 FY | -38.8 Million USD | -112.02% |
| 1993 Q1 | -9.2 Million USD | -50.82% |
| 1992 Q3 | -5.6 Million USD | -60.0% |
| 1992 Q1 | -3.2 Million USD | 13.51% |
| 1992 FY | -18.3 Million USD | -90.63% |
| 1992 Q4 | -6.1 Million USD | -8.93% |
| 1992 Q2 | -3.5 Million USD | -9.38% |
| 1991 Q1 | 2 Million USD | 128.57% |
| 1991 Q3 | -2.5 Million USD | -25.0% |
| 1991 Q4 | -3.7 Million USD | -48.0% |
| 1991 FY | -9.6 Million USD | -190.91% |
| 1991 Q2 | -2 Million USD | -200.0% |
| 1990 Q1 | 1.2 Million USD | 0.0% |
| 1990 FY | -3.3 Million USD | 0.0% |
| 1990 Q4 | -7 Million USD | -638.46% |
| 1990 Q3 | 1.3 Million USD | 8.33% |
| 1990 Q2 | 1.2 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | 2492.172% |
| Dynavax Technologies Corporation | -37.02 Million USD | 11029.837% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 76909.641% |
| Perrigo Company plc | 151.9 Million USD | -2564.319% |
| Illumina, Inc. | -1.06 Billion USD | 478.587% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 40.996% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 978.736% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 128.752% |
| IQVIA Holdings Inc. | 1.97 Billion USD | -104.709% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 3758.726% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 9160.604% |
| Waters Corporation | 817.67 Million USD | -394.952% |
| Biogen Inc. | 1.29 Billion USD | -212.084% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 1577.017% |
| Evolus, Inc. | -49.23 Million USD | 8320.299% |
| Adicet Bio, Inc. | -152.03 Million USD | 2761.9% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 3431.084% |
| bluebird bio, Inc. | -244.26 Million USD | 1756.868% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 2701.583% |
| FibroGen, Inc. | -281.81 Million USD | 1536.084% |
| Agilent Technologies, Inc. | 1.35 Billion USD | -199.785% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 9078.133% |
| Homology Medicines, Inc. | -48.25 Million USD | 8486.903% |
| Geron Corporation | -193.94 Million USD | 2186.736% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 1534.252% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 5606.708% |
| Myriad Genetics, Inc. | -123.7 Million USD | 3371.706% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 4113.905% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 885.401% |
| Zoetis Inc. | 3.06 Billion USD | -31.87% |
| Abeona Therapeutics Inc. | -48.2 Million USD | 8496.473% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | -272.221% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | -1981.403% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 6.045% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 10436.628% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 1244.121% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 1566.309% |
| Verastem, Inc. | -92.08 Million USD | 4495.009% |
| Nektar Therapeutics | -137.42 Million USD | 3044.952% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 1845.756% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 4256.969% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 1611.104% |
| OPKO Health, Inc. | -157.02 Million USD | 2677.426% |
| Exelixis, Inc. | 170.88 Million USD | -2268.318% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | -1513.033% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -3672.394% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 7358.591% |
| uniQure N.V. | -282.87 Million USD | 1530.723% |
| Imunon, Inc. | -21.03 Million USD | 19344.019% |
| Blueprint Medicines Corporation | -486.27 Million USD | 932.262% |
| Insmed Incorporated | -709.62 Million USD | 670.315% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | -1098.878% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 1133.776% |
| TG Therapeutics, Inc. | 20.63 Million USD | -19514.695% |
| Incyte Corporation | 620.52 Million USD | -552.206% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 657.145% |